Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
BörsenkürzelSDGR
Name des UnternehmensSchrodinger Inc
IPO-datumFeb 06, 2020
CEODr. Ramy Farid, Ph.D.
Anzahl der mitarbeiter891
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse1540 Broadway
StadtNEW YORK
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl10036
Telefon15032991150
Websitehttps://www.schrodinger.com
BörsenkürzelSDGR
IPO-datumFeb 06, 2020
CEODr. Ramy Farid, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten